Lu Xu

Lu Xu, Ph.D., Vice President, Developmental Science, joined Bolt Biotherapeutics in 2022, bringing 20 years of experience in the development of a range of antibody-based therapeutics, primarily in the field of oncology. Over the course of her career, Dr. Xu has led or supported new drug development programs from early-stage research through post-marketing commitment, including 12 INDs and two BLAs. Before joining Bolt, Dr. Xu was co-founder and head of drug development at PRAV Biosciences. Prior, she was head of preclinical development and clinical pharmacology at 23andMe Therapeutics, where she oversaw preclinical safety assessment, pharmacokinetics, biomarker discovery, and bioanalytics. Dr. Xu also served as the head of clinical pharmacology and preclinical pharmacokinetics at OncoMed Pharmaceuticals (now Mereo BioPharma Group), supporting the planning and execution of multiple oncology programs from pre-IND stage through Phase 2 clinical studies. Before joining OncoMed, she held drug development positions of increasing responsibility at Genentech, a member of the Roche Group, and Novartis.

Dr. Xu earned a Ph.D. in biomedical engineering and an M.S. in regulatory science from the University of Southern California, and an M.S. in biochemistry from University of California, Riverside.